Year: 2025

Mandalay Resources Delivers Strong Q4 Gold and Antimony Performance, Achieves Top End of 2024 Production Guidance Leading to $76 Million Cash Balance

Written by Customer Service on January 13, 2025. Posted in Earnings Releases And Operating Results.

TORONTO, Jan. 13, 2025 (GLOBE NEWSWIRE) — Mandalay Resources Corporation (“Mandalay” or the “Company”) (TSX: MND, OTCQB: MNDJF) announces strong operating results for the fourth quarter and full-year 2024. All currency references in this press release are in U.S. dollars, except as otherwise indicated. Fourth Quarter 2024 Highlights:Consolidated production of 25,496 gold equivalent ounces:Costerfield achieved its strongest quarter of 2024, producing 15,768 gold equivalent ounces; Björkdal delivered stable production of 9,728 gold ounces.Full-Year 2024 Highlights:Delivered 97,128 gold equivalent ounces, approaching the top end of the 2024 production guidance range of 90,000 to 100,000 gold equivalent ounces;Gold: 85,669 ounces produced; Antimony: 1,282 tonnes produced;Year-end cash balance...

Form 8.3 – [ALLIANCE PHARMA PLC – Opening Disclosure – 10 01 2025] – (CGAML)

Written by Customer Service on January 13, 2025. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree ALLIANCE PHARMA PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Form 8.3 – [ALLIANCE PHARMA PLC – 10 01 2025] – (CGWL)

Written by Customer Service on January 13, 2025. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree ALLIANCE PHARMA PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Form 8.3 – [LOUNGERS PLC – 10 01 2025] – (CGWL)

Written by Customer Service on January 13, 2025. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary Clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree LOUNGERS PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Form 8.3 – [LEARNING TECHNOLOGIES GROUP PLC – 10 01 2025] – (CGWL)

Written by Customer Service on January 13, 2025. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree LEARNING TECHNOLOGIES GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

Written by Customer Service on January 13, 2025. Posted in Public Companies.

Preliminary, unaudited revenue for the full year 2024 of approximately $174 million Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th, 2024, at 9:45 a.m. PT. SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) — Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2024. Standard BioTools expects fourth quarter 2024 revenue of approximately $46.5 million and full year 2024 revenue of approximately $174 million. “The team worked hard in a difficult environment to deliver on the top end of our revised annual guidance forecast, adjusted in the second quarter to account for the ongoing and industry-wide headwinds,” said Michael Egholm, PhD, Chief Executive Officer of Standard...

Schouw & Co. share buy-back programme, week 2 2025

Written by Customer Service on January 13, 2025. Posted in Public Companies.

On 2 January 2025, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 70 of 23 December 2024. Under the programme, Schouw & Co. will acquire shares for up to DKK 50 million during the period 2 January to 31 March 2025. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount Accumulated until 3 January 2025 3,100 551.56 1,709,821 Monday, 6 January 2025 1,600 556.62 890,592 Tuesday, 7 January 2025 1,600 552.70 884,320 Wednesday, 8 January 2025 1,700 546.94 929,798 Thursday, 9 January 2025 1,800 545.89 982,602 Friday,...

EDAP Announces Preliminary Record Fourth Quarter Focal One® System Sales and Record U.S. Procedures

Written by Customer Service on January 13, 2025. Posted in Public Companies.

Company Reports Preliminary Worldwide Record Fourth Quarter Sales of 11 Focal One Systems Record U.S. Fourth Quarter Focal One System Sales Record Number of U.S. Focal One Procedures, with Year-Over-Year Growth of 30% PDF Version AUSTIN, Texas, January 13, 2025 — EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced preliminary record Focal One System sales for the fourth quarter of calendar year 2024. The Company experienced robust demand for its Focal One Robotic HIFU technology, reporting preliminary record fourth quarter of 11 Focal One Systems. “Our strong fourth quarter performance reflects the growing adoption of our industry-leading Focal One Robotic HIFU technology platform, which is fundamentally transforming how urologists manage prostate cancer,”...

Braves Announce Exclusive Gray Media Spring Training Action

Written by Customer Service on January 13, 2025. Posted in Public Companies.

Ten Atlanta Braves Spring Training Games will be Available for Fans to Watch on Gray Media Network of Stations in 2025 ATLANTA, Jan. 13, 2025 (GLOBE NEWSWIRE) — Atlanta Braves fans will be able to watch more Spring Training action than ever before as the team makes ten Spring training games available across two dozen Gray Media stations, beginning with the February 27 game versus the Washington Nationals. As part of the Braves’ new partnership with Gray Media announced last month, the ten Spring Training games will be exclusively broadcast on local television stations in 24 markets across the Southeast. The Gray schedule includes the second annual Major League Baseball Spring Breakout game, which will feature top prospects from the Braves and the Detroit Tigers on March 16. The Gray Media broadcast schedule for Spring 2025 is...

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Written by Customer Service on January 13, 2025. Posted in Public Companies.

More Than 40 Adult Sickle Cell Disease Patients Now Enrolled in BEACON Trial of BEAM-101; Beam Expects to Dose 30 Patients and Present Updated Data by Mid-2025 Initial Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency Expected in First Half 2025 Dosing Anticipated to Commence in Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type 1a in Early 2025 IND-enabling Studies of ESCAPE Nongenotoxic Conditioning Approach Underway, with Healthy Volunteer Study of BEAM-103 Antibody Expected to Initiate by Year-end Cash Runway Expected to Support Operating Plans into 2027, Now Inclusive of Commercial Readiness Activities for BEAM-101 Cambridge, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today...

Year: 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals